MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Alector Historical Prices 2011-2026 | ALEC
Annual Historical Prices Alector
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4 | 1.69 | 7.02 | 8.56 | 15.9 | 16.8 | 27.9 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 27.9 | 1.69 | 11.5 |
Historical Prices of other stocks in the Biotechnology industry
| Issuer | Historical Prices | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
18.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Amgen
AMGN
|
369 | $ 350.54 | 0.79 % | $ 189 B |  USA |
 |
Amphastar Pharmaceuticals
AMPH
|
26.7 | $ 19.39 | -0.56 % | $ 906 M | USA |
 |
Altimmune
ALT
|
3.61 | $ 3.45 | 3.14 % | $ 304 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
1.66 | $ 1.4 | 1.82 % | $ 357 M |  Britain |
 |
I-Mab
IMAB
|
0.68 | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
3.36 | - | 2.54 % | $ 160 B |  France |
 |
Aytu BioScience
AYTU
|
2.51 | $ 2.62 | 0.21 % | $ 16.5 M | USA |
 |
Biophytis SA
BPTS
|
0.33 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
216 | $ 219.22 | -1.2 % | $ 5 B |  Danmark |
 |
Midatech Pharma plc
MTP
|
0.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.3 | - | - | $ 26.5 M | USA |
 |
Benitec Biopharma
BNTC
|
13.5 | $ 11.01 | 0.27 % | $ 453 M | USA |
 |
ARCA biopharma
ABIO
|
28.8 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
5.72 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
13 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
13.5 | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
28.5 | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
2.13 | - | 10.36 % | $ 9.8 M | USA |
 |
Compugen Ltd.
CGEN
|
2.1 | $ 2.12 | 1.44 % | $ 198 M |  Israel |
 |
Acasti Pharma
ACST
|
3.37 | - | 4.01 % | $ 150 M | Canada |
 |
Coherus BioSciences
CHRS
|
1.93 | $ 1.58 | 3.95 % | $ 185 M | USA |
 |
Avenue Therapeutics
ATXI
|
0.42 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
3.86 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
0.77 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
0.31 | - | -9.65 % | $ 45.9 M | USA |
 |
Cellectis S.A.
CLLS
|
3.34 | $ 3.39 | 1.5 % | $ 116 M | France |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
2.46 | $ 0.6 | -1.79 % | $ 6.87 M | Israel |
 |
Ayala Pharmaceuticals
AYLA
|
0.5 | - | - | $ 7.46 M | Israel |
 |
Cullinan Management
CGEM
|
14.9 | $ 12.85 | 0.86 % | $ 774 M | USA |
 |
Atreca
BCEL
|
1.27 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
3.1 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
185 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
13.3 | - | -10.95 % | $ 876 K | USA |
 |
CorMedix
CRMD
|
6.33 | $ 6.43 | 2.88 % | $ 463 K | USA |
 |
Cara Therapeutics
CARA
|
1 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
26.9 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
8.23 | - | -74.18 % | $ 955 K | USA |
 |
CytomX Therapeutics
CTMX
|
6.75 | $ 4.41 | -1.01 % | $ 608 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
4.04 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
2.04 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
12 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
19.3 | - | - | $ 867 M | Germany |
 |
Denali Therapeutics
DNLI
|
18.5 | $ 21.1 | 4.59 % | $ 3.47 B | USA |
 |
Dyadic International
DYAI
|
1.67 | $ 0.9 | -4.79 % | $ 25.9 M | USA |
 |
Akero Therapeutics
AKRO
|
48.4 | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
2.68 | $ 4.29 | 1.06 % | $ 712 M | Canada |